AIG scored an exit as genetic disease and cancer drug developer BridgeBio Pharma floated above its range while increasing the number of shares in its IPO.

BridgeBio Pharma, the US-based Mendelian disease therapy developer backed by insurance group AIG, floated on the Nasdaq Global Market yesterday in an initial public offering sized at approximately $349m. The offering consisted of 20.5 million shares issued at $17.00 each, above the IPO’s $14 to $16 range. The company also increased the number of shares…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.